NCIt definition : An orally bioavailable cholecystokinin (CCK) receptor antagonist, with gastric acid
reducing and potential antineoplastic activities. Upon oral administration, proglumide
binds to and blocks both cholecystokinin receptor type A (CCK-AR; CCK1-R) and gastrin/cholecystokinin
type B receptor (CCK-BR; CCK2-R). This prevents the binding of cholecystokinin and
gastrin to the CCK receptors, and inhibits both gastrointestinal (GI) motility and
gastric secretions. This may also decrease fibrosis in the tumor microenvironment
(TME), increase both the infiltration of T-cells and the penetration of chemotherapeutic
agents, and inhibit tumor growth and metastasis. CCK receptors, normally expressed
in the GI tract and the nervous system, are overexpressed on fibroblasts and certain
cancers.;
UNII : EPL8W5565D;
InChIKey : DGMKFQYCZXERLX-UHFFFAOYSA-N;
CAS number : 6620-60-6; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 6620-60-6
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;